Interleukin-6 (IL-6) has been shown to regulate both growth and neuroendocrine (NE) differentiation in some types of human cancer cells and erbB2 may be a critical component of IL-6 signaling. Non-small cell lung cancer (NSCLC) tumors that demonstrate NE properties have been suggested to have biological characteristics similar to small cell lung cancers with initial responsiveness to chemotherapy. We investigated whether IL-6 is implicated in the cell growth, NE differentiation, and chemosensitivity of NSCLC-NE cells. NSCLC-NE cells were treated with exogenous IL-6, and a subclone of an IL-6-transfected NSCLC cell line that constitutively expressed IL-6 receptor was also generated. These cells were assessed for cell proliferation by cell counting and MTT assays, chemosensitivity to cisplatin and etoposide by MTT assays, and NE differentiation by observing morphological changes and immunoblotting for neuron specific enolase (NSE). The IL-6 treated cells and the IL-6 transfected cells showed enhanced cell proliferation and down-regulated NSE expression, but little change in chemosensitivity. In the culture medium, IL-6 transfected cells grew as looser aggregates than the parental cells. IL-6 could not activate the erbB genes. In conclusion, IL-6 can induce cell proliferation and NE de-differentiation but has little effect on chemosensitivity in IL-6 receptor expressing NSCLC-NE cells. The status of NSE expression is unlikely to be a crucial factor for chemosensitivity in NSCLC cells.
INTRODUCTION
Interleukin-6 (IL-6), a pleiotropic cytokine with a wide range of biological activities in immune regulation, hematopoiesis, inflammation, and oncogenesis, is produced by various types of human normal and transformed tumor cells and involved in regulation of the immune response, acute phase reaction, and cell proliferation (17, 27, 30) .
Consistent with this prominent role in cell proliferation, IL-6 has been detected in primary squamous cell carcinomas, adenocarcinomas and sarcomas, as well as in tumor cell lines (13, 18, 25, 39) . It has been suggested that IL-6 may play a significant role in the pathophysiology of cancer and it is a potential mediator in the development of cancer cachexia (13, 39) . Several clinical reports have highlighted the prognostic importance of IL-6 in a variety of human solid tumors, including prostate, breast, colon, renal, bladder, ovary, and lung cancers (3, 10, 22, 44) , suggesting that circulating IL-6 level is correlated with the extent of disease and disease recurrence, and is associated with worse survival. In some of these tumors, higher levels of were found in patients who were unresponsive to hormone therapy, radiotherapy or chemotherapy (7, 10, 29) . However, whether IL-6 is directly involved in the development of treatment resistance is as yet unclear.
Neuroendocrine (NE) differentiation has been found in a subgroup of a variety of carcinomas, including prostate, breast, gastric and colorectal cancers, and non-small cell lung cancer (NSCLC) (2, 5, 8, 23, 45) . In some of these tumors, NE differentiation may suggest an adverse influence on patient survival (2, 5) .
Several recent studies with prostate cancer cells have demonstrated that IL-6 can promote NE differentiation through different intracellular signal transduction pathways, including the phosphatidylinositol 3-kinase/epithelial and endothelial tyrosine kinase (PI3-kinase/Etk) pathway (33) , signal transducers and activators of transcription 3 (STAT3) pathway (38) , and mitogen-activated protein kinase (MAPK) pathway (21, 34) . The protein of erbB2 gene, one member of the erbB gene family, is shown to be a critical component of IL-6 signaling through the MAPK pathway (34) .
Data suggest that IL-6 acts as an autocrine and paracrine growth factor in hormone refractory human prostate cancer cell lines and, in contrast, as a paracrine growth inhibitor in hormone dependent cell lines (7) . 3 Clinically and biologically, lung cancer is generally divided into small cell lung cancer (SCLC) and NSCLC. Increased serum level of IL-6 was found in 39% of lung cancer patients, whereas IL-6 was not detected in the serum of healthy people as well as patients with benign lung diseases (44) . Bihi et al. have demonstrated that IL-6 may be required in the control of cell proliferation in a subset of NSCLC cell lines and there are two subgroups of NSCLC, IL-6 dependent and independent (6) .
Paradoxically, anti-tumor effects of IL-6 have been demonstrated in vitro and in vivo in patients with NSCLC and breast cancer (42) . The real role of IL-6 in lung cancer still needs further study.
While SCLC is responsive to chemotherapy, NSCLC is only moderately responsive to such therapy at the time of diagnosis. SCLC has distinct NE properties and is recognized as one of the NE neoplasms. In contrast, only about 10-20% of NSCLC tumors have NE properties (NSCLC-NE) (26) . These express multiple NE cell markers, including neuron specific enolase (NSE), L-dopa decarboxylase, chromogranin A, synaptophysin, and cytoplasmic dense core granules. Among these markers, NSE, a glycolytic enzyme enolase, has been detected in tissue extracts derived from either brain or various NE tissues. NSE is a specific biochemical marker for both neurons and peptide-secreting NE cells, as well as a useful index of neuronal differentiation. NSE is the only marker that can be utilized to identify all the NE cells in the lung (28) , the NE marker most frequently detected in NSCLC (38%) and, most importantly, is probably a prognostic marker of clinical relevance (16) .
Previously, Gazdar et al. have shown that NSCLC-NE cell lines are as chemosensitive as SCLC cell lines, while NSCLC lines lacking NE markers are relatively chemoresistant. They suggested that NE cell differentiation may delineate a relatively chemoresponsive subset of NSCLC, and could be used as a predictor of better prognosis (12) . However, the association of the presence of NE markers with an increased likelihood of response to chemotherapy and a better prognosis in patients with NSCLC is less consistent. Some have found that NE differentiation predicts chemoresponsiveness (8, 15) , but others have failed to demonstrate any correlation with chemosensitivity (11, 14, 16, 36) . Similar discrepancies have also been observed in terms of patient survival (1, 5, 8, 11, 14, 19, 24, 32, 36, 37) . Moreover, the evidence of direct correlation of NE differentiation with tumor chemosensitivity at the molecular level in NSCLC is still lacking.
Data demonstrated survival was poorer in patients with NSCLC whose tumor 4 expressed a high level of erbB2 than in those with tumors expressing lower levels (20, 40) , suggesting that erbB2 is a prognostic factor for patients with NSCLC. Data also suggested that erbB2 may be a predictor of response to chemotherapy (4, 41) .
Thus far, the association between IL-6 and NE differentiation in NSCLC has not been identified. We are interested in the relationships between HER-2/neu expression, NE differentiation, and chemosensitivity in NSCLC cells. We therefore conducted this study to investigate the effects of IL-6 on the expression of erbB genes and biological features, including cell growth, NE differentiation, and chemosensitivity, in NSCLC-NE cells. We demonstrated that IL-6 could stimulate cell growth and down-regulate the expression of NSE, while exhibiting very little change in chemosensitivity in IL-6 receptor expressing NSCLC-NE cells. The biological effects of IL-6 are not associated with the erbB signaling.
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MATERIALS AND METHODS
NSCLC-NE Cells and Cell Culture
Three lung adenocarcinoma cell lines, National Cancer Institute (NCI)-H1155, NCI-H1355 and NCI-H820, were selected for this study. These three cell lines exhibited NE properties (26) and were established and characterized at the NCI-Navy Medical Oncology Branch (Division of Cancer Treatment, NCI, Bethesda, MD) from tumor specimens obtained from previously untreated patients. All these cell lines were cultured and maintained in serum-free ACL-4 medium (Life Technologies, Inc., Grand Island, NY) unless otherwise indicated. Cells were cultured in a humidified atmosphere of 5% CO2 at 37°C. Cultured cells were observed and cells in log phase growth were photographed in phase contrast with a Nikon ECLIPSE TE-300 inverted microscope.
Establishment of IL-6 Expression Stable Transfectants
The recombinant human IL-6 (rhIL-6) constitutive expression construct pCMV-IL-6, which carries 0.64-kb full-length IL-6 cDNA (43) non-diluted supernatants or standard human IL-6. After incubating the plate with a biotinylated anti-IL-6 conjugate for 2 h at room temperature, it was washed, and a substrate solution was added. The reaction was stopped with 1M sulfuric acid and the resulting color was read at 450 nm with a microplate reader. Data of eight independently performed assays were obtained; each assay was done in duplicate.
Cell Growth
Cell growth in the presence and absence of IL-6 were determined using the 6 tetrazolium dye colorimetric (MTT) assay for cells in log phase. The assay is well suited for precise analysis of cell growth and growth factor effects because the cell number is directly proportional to MTT reduction under defined conditions, and a doubling of optical density indicates a doubling of cell number (31) . Cells were harvested and washed three times in phosphate buffered saline (PBS), then were plated at the appropriate seeding density in 180 µl of medium into 96-well microtiter plates. After approximately 16 h of incubation at 37°C in a 5% CO 2 atmosphere, 20 µl of the test solutions, which consisted of culture medium plus IL-6 at a final concentration of 0, 5 or 50 ng/ml, were added to each well. Cell density was determined by preliminary experiments and assay conditions were established so that growth of the tumor cells remained constant through the analysis period.
There were five replicate plates prepared for each cell line per test. After addition of IL-6, the microtiter plates were incubated. For each cell line, the MTT assay was performed immediately after adding IL-6 (day 0) and one plate per day for four more succeeding days as described previously (41) . Each data point, representing the mean value from eight culture wells, was used for the construction of growth curves. Each experiment was done three times. culture medium with and without IL-6 (50 ng/ml). Culture medium with assigned concentration of rhIL-6 was changed every 2 days and cells were harvested after incubation for 0, 2, 4, and 6 days. Cells were disaggregated with a trypsin-EDTA solution, neutralized, and resuspended in culture medium. Viable cell counts were determined by trypan blue exclusion using a hemocytometer. The mean of the hemocytometer counts of cells from triplicate flasks was determined every other day for six days for the construction of growth curves and to determine doubling times.
The reported results were the means of three independently performed experiments.
Paired t-tests were performed to evaluate whether significant differences in cell proliferation occurred between the tested conditions. All tests were two sided, and significance was assumed if p < 0.05.
Immunoblottings of rhIL-6 Treated Cells
After being plated at the appropriate seeding density for 24 h, cells were incubated with rhIL-6 (0, 50, and 100 ng/ml) for six days. Culture medium with the assigned 7 concentration of rhIL-6 was changed every two days and cells were harvested after incubation for 0, 2, 4, and 6 days for evaluating NSE expression. To ascertain erbB expression, cells were cultured in RPMI 1640 for 16 h, incubated without or with rhIL-6 (50, 100, and 200 ng/ml) or Neu differentiation factor (NDF) ( Blots were incubated with primary antibody (anti-erbB1, anti-erbB2, anti-erbB3, anti-NSE, or anti-β-actin) for 1 h at room temperature, and washed three times with PBS-T. The blots were then incubated with horseradish peroxidase-conjugated secondary antibody for 1 h, washed three times with PBS-T, and then developed using an enhanced chemiluminescence technique (LumiGLO; KPL Inc., Gaithersburg, MD) and exposed to BioMax Film (Kodak, Rochester, NY). The same blot was stripped and reprobed for β-actin. The experiments were performed in triplicate.
RT-PCR of IL-6 and IL-6 Receptor
Total RNA was isolated using the Tri-Reagent (Sigma Chemical Co., St. Louis, MO) following the manufacturer's instructions. Five micrograms of total RNA were used for each RT reaction using the Superscript II reagent (Invitrogen, Carlsbad, CA).
PCRs were performed using Taq DNA polymerase (BioTools, Edmonton, AB) with 
Drug Testing with or without IL-6
In vitro drug sensitivity testing was performed using the MTT assay. Cells were washed three times with PBS, disaggregated, resuspended in the ACL-4 medium, and seeded in 160 µl at the appropriate seeding density into 96-well microtiter plates.
After approximately 16-h incubation, 20 µl of rhIL-6 (a final concentration of 0, 5, or 50 ng/ml) plus 20 µl of cisplatin or etoposide (final concentration of 0, 0.031, 0.1, 0.31, 1, 3.1, or 10 µM) were added to the control and test wells. After exposure to the drug with or without rhIL-6 for 4 days, the remaining steps of the assay were performed as previously described (41) . Each assay was done in eight replicate wells and the experiment was performed in triplicate on each of the cell lines. The results were reported as IC50 values that were the means of three independently performed assays and were defined as the drug combination required to inhibit cell growth by 50%.
Reagents
Human recombinant IL-6 (rhIL-6) and NDF (neu differentiation factor; her-reguline) were purchased from R&D Systems, Inc. 
RESULTS
Expression of NSE in NSCLC-NE Cells
Though the neuroendocrine properties of the three tested cell lines had been well characterized (26) , the expression of NSE, the major neuroendocrine marker, was confirmed by immunoblotting with specific antibody. As shown in Fig. 1A , the NCI-H1155 cell line expressed the highest and the NCI-H1355 cell line expressed the lowest levels of NSE.
Expression of IL-6 and IL-6 Receptor and Effects of rhIL-6 on Cell Proliferation
We determined the expression of IL-6 and IL-6 receptor of the tested cell lines by The growth curves with and without rhIL-6 treatment determined by MTT assays are shown in Fig. 2 . Exogenous rhIL-6 had very little effect on cell proliferation of NCI-H1155 ( Fig. 2A, left panel) , which expressed undetectable IL-6 and IL-6 receptor. Exogenous rhIL-6 produced a minimal but statistically significant growth stimulation (p < 0.05) of the cell line NCI-H1355 ( Fig. 2A middle panel ), which expressed a high level of IL-6, but a relatively lower level IL-6 receptor (Fig. 1B) . In contrast, rhIL-6 markedly enhanced NCI-H820 cell growth (p < 0.001) in a dose-dependent manner ( Fig. 2A, right panel) . The NCI-H820 cell line expressed a minimal amount of IL-6 but a relatively higher level of IL-6 receptor (Fig. 1B) . These findings suggested that the growth effect of rhIL-6 was correlated with the expression level of IL-6 receptor. Growth curves that were determined by direct cell counting confirmed the growth stimulation of rhIL-6 on the NCI-H820 cells (Fig. 2B) . As compared to the growth of control cells with no IL-6 treatment, cell growth of H820 was increased to approximately 150% after rhIL-6 (50 ng/ml) treatment for four days (by MTT assay, Fig. 2A right panel) or six days (by direct counting, Fig. 2B ). All the p values were less than 0.001.
Down-Regulation of NSE Expression by IL-6 in NSCLC-NE Cells
It has been reported that IL-6 up-regulates the expression of NSE in the human prostate cancer cell line LNCaP (23, 40, 45) . To evaluate the long-term effect of IL-6 on NE marker expression, we treated the NCI-H820 cell line (a high IL-6 receptor and NSE expressor) with 50 ng/ml and 100 ng/ml rhIL-6 for 6 days. The results showed that NSE expression was down-regulated by rhIL-6 after treatment for longer than 2 days in the NCI-H820 cell line and there were very similar effects at concentrations of 50 ng/ml and 100 ng/ml (upper panel). In the NCI-H1355 cells, treatment with rhIL-6 at 50 ng/ml for 4 and 6 days also down-regulated NSE (lower panel, left), but to a less degree when compared with its effect on the H820 cells. In contrast, rhIL-6 showed no detectable effects on NSE expression in the IL-6 receptor lacking NCI-H1155 cells (lower panel, right) . These findings demonstrated a trend suggesting that the effect of rhIL-6 on NSE expression was dependent on the expression status of IL-6 receptor in this panel of NSCLC-NE cell lines.
Crucial Role of IL-6 in Cell Proliferation and NSE Regulation in H820
We have demonstrated that IL-6 exhibited profound effects on cell proliferation and NSE expression in the NCI-H820 cell line. To corroborate these findings and elucidate the biological role of IL-6 in the H820 cells, we transfected a rhIL-6 constitutive expression construct into this cell line and generated a stably rhIL-6 overexpressing subclone, which was designated "H820.ILSC." As shown in Fig. 1B, the endogenous IL-6 was very low in the parental H820 cell line, therefore the transfected form would be the major source of IL-6 produced by the cells in these experiments.
To examine whether IL-6 was increased in the H820.ILSC, we detected the level of IL-6 mRNA and the amount of secret protein using RT-PCR and ELISA, respectively.
As shown in Fig. 4A , IL-6 expression at the mRNA level and production of protein product in the culture medium of the H820.ILSC were much higher than those of the parental and the vector control lines (30-fold and 250-fold, respectively). Expression of NSE was also examined by RT-PCR and Western blot and found to be markedly down-regulated at the mRNA and the protein levels in the H820.ILSC cells (Fig. 4B) .
The findings were consistent with the results found in the rhIL-6 treated H820 cells (Fig. 3, upper panel) .
To determine whether IL-6 produced by the H820.ILSC cells might affect growth in an autocrine manner, we examined the cell proliferation of the H820.ILSC cells.
Notably, the H820.ILSC cells exhibited a significantly increased growth rate (2.7-fold, p < 0.001) as compared with the parental and the vector control lines (Fig. 4C) . Taken together, our findings identified IL-6 as a crucial factor capable of triggering cell 11 proliferation and modulating NE differentiation in NSCLC-NE cells.
Morphological Change in the IL-6 Transfected NCI-H820 Cells
To further assess the effect of IL-6 on cell growth, we continuously observed and recorded the morphological difference between IL-6 constitutively expressing stable clone H820.ILSC and the parental cell line. In contrast with compact globelets of the parental and H820.SC control cells, the aggregates of the H820.ILSC cells grew loosely and un-globally after incubation for longer than 2 weeks (Fig. 5) .
No Activation of erbB Signaling in IL-6 Treated H820 Cells
A previous report demonstrated that IL-6 might induce NE differentiation through erbB2 signaling in a prostate cancer NE cell line LNCaP (8) . Presently, Western blots revealed detectable levels of erbB1, erbB2 and erbB3 in the NCI-H820 cell line (Fig.   6 ). To study the possibility of involvement of the erbB2 signaling in the IL-6 induced biological alterations, we examined the expression of erbB genes in the H820 cells with or without rhIL-6 treatment by Western blotting. We found that NDF but not rhIL-6 (from 50 ng/ml to 200 ng/ml) could induce tyrosine phosphorylation at ∼185 Kd, indicating that IL-6 was not able to activate erbB genes (Fig. 6) . Although the antibody used for this blot was non-specific and could detect all of the activated tyrosine kinases, the IL-6 treated cells showed no evidence of tyrosine kinase activation at ∼ 185 Kd when compared to the NDF treated cells, indicating that neither erbB2 nor erbB3 was activated by IL-6.
Little Effect on Chemosensitivity by IL-6 in H820
Thus far, whether NE differentiation confers drug sensitivity to NSCLC-NE cells has not been clarified. In this study, we took the advantage of the finding that IL-6 down-regulated the expression of NSE to examine the influence of NE differentiation on drug sensitivity of the tested cells. The chemosensitivities (expressed as the IC50 value) to two commonly used anticancer agents (cisplatin and etoposide) were determined in the H820, H820.SC and H820.ILSC cell lines as well as in the H820 cell line in the absence or presence of 5 or 50 ng/ml exogenous rhIL-6. As shown by the dose-effect curves and the mean values of IC50 (Fig. 7) , the response of the test cell lines were very similar to the same anticancer agent. These results indicated that NSE expression modulated by adding exogenous IL-6 or by endogenous IL-6 production was not related to chemosensitivity in NSCLC-NE cells. We previously reported that overexpression of erbB2 in NSCLC cells correlated with intrinsic resistance to chemotherapy (41) . Studies suggested that differentiation of prostate NE cells might be associated with activation of the erbB protein (34) , and erbB2 might be a critical component of IL-6 signaling through the MAP kinase pathway. In the present study, however, our data demonstrated that erbB genes are unlikely to be involved in the signaling of the IL-6 induced biological alterations in NSCLC-NE cells.
In conclusion, IL-6 stimulates cell proliferation and induces NE de-differentiation in IL-6 receptor expressing NSCLC-NE cells. Our finding that no obvious changes in the chemosensitivities to etoposide and cisplatin occur in vitro in NSCLC-NE cells after cellular modulation of NSE expression by IL-6 suggests that IL-6 production or expression of NE features is unlikely to be a crucial determinant for chemosensitivity in NSCLC cells. receptor expressors H820 and H1355, but not in the receptor lacking H1155 (A, statistical significance: * p < 0.05 and ** P < 0.001 as compared with the control cells with no rhIL-6 treatment). H820 expressed a higher level of IL-6 receptor and exhibited more rhIL-6 induced growth stimulation than H1355. In H820, rhIL-6 stimulated cell growth in a dose-dependent manner (A, right panel, rhIL-6 50 ng/ml induced more cell growth than 5 ng/ml, ¶ P = 0.017). Fig. 3 . Effects of exogenous rhIL-6 on NSE expression. NSE expression was down-regulated obviously after rhIL-6 treatment for 4 days and 6 days in H820 and there was little difference between the effects of 50 and 100 ng/ml (upper panel). In the NCI-H1355 cells, rhIL-6 (50 ng/ml) treatment for 4 and 6 days also down-regulated NSE, but to a lesser degree when compared with the effects on H820 (lower panel, left) . In contrast, rhIL-6 showed no detectable effects on NSE 23 expression in the IL-6 receptor lacking H1155 (lower panel, right). Numbers in parentheses are the levels of NSE, which are expressed in arbitrary units relative to the value of control cells, to which a value of 1 has been assigned. NSE levels were also normalized by densitometry of the β-actin signal. 
